Evidence gaps include limited topline safety granularity, unknown long-term follow-up and retreatment rates, and lack of ...
Amgen announces positive phase 3 results for subcutaneous Tepezza in adults living with moderate-to-severe active thyroid eye disease: Thousand Oaks, California Wednesday, April 8 ...
The TEPEZZA OBI trial evaluated the safety and efficacy of SC teprotumumab in patients with active TED and proptosis of 3mm or greater from baseline.
A subcutaneous monoclonal antibody induced greater reductions in proptosis at 24 weeks than placebo for people with active ...
A phase 3 trial of patients with moderate-to-severe TED has shown that subcutaneous injection of Tepezza by way of an on-body ...
Safety findings aligned with prior batoclimab experience, with no emergent safety liabilities reported across the phase 3 ...
The trial met its primary endpoint, demonstrating a statistically significant 77% proptosis response rate at 24 weeks.
Participants did demonstrate greater proptosis improvement from baseline following the initial high dose period vs after the ...
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced new pooled efficacy data from the Phase 2 and 3 clinical trials of TEPEZZA™ (teprotumumab-trbw) showing that the ...
Zacks Investment Research on MSN
AMGN's subcutaneous Tepezza scores phase III win in thyroid eye disease
Amgen AMGN announced positive top-line results from a late-stage study evaluating the subcutaneous (under the skin or SC) ...
Researchers from the Schepens Eye Research Institute of Massachusetts Eye and Ear have identified new underlying mechanisms of proptosis, or bulging of the eyes, in patients with acute thyroid eye ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results